

## アンジオテンシン受容体ネプリライシン阻害薬は ACE阻害薬より優れている (LBS.05 Abstract 19328)

PIONEER-HF: sacubitril/バルサルタンは安定した急性心不全のバイオマーカーを改善させる

PIONEER-HF: Sacubitril/valsartan shows biomarker benefit in stabilized acute heart failure

慢性心不全患者に使用される薬物療法は、急性心不全で入院した患者の予後不良マーカーをも改善する、と *New England Journal of Medicine* に掲載され、American Heart Association Scientific Sessions 2018 で発表された。アンジオテンシン受容体ネプリライシン阻害薬 sacubitril/バルサルタンを内服している患者において、バイオマーカー NT-proBNP は標準治療を行われた患者よりも迅速に低下した。改善の徴候は、1 週間と早い段階で認められた。他のバイオマーカーもまた、sacubitril/バルサルタンにより改善した。この結果は、この薬剤が急性に悪化した心不全患者の予後を改善し得ること、およびこれらの患者の標準治療となり得ることを示唆している。

### Full Text

A drug therapy used for patients with chronic heart failure also improves markers of poor prognosis in individuals who are hospitalized with acute heart failure, new Yale-led research shows. The findings suggest that the drug can improve outcomes for acutely ill heart patients and potentially become the new standard of care for treating this serious condition, the researchers said.

The study was published in the *New England Journal of Medicine*, and presented at the American Heart Association Scientific Sessions 2018.

Acute heart failure is the leading cause of hospitalizations for older adults. Affected individuals experience high rates of re-hospitalization and death. The standard of care, which consists of diuretics and medications that enhance blood flow, has remained largely unchanged for decades.

To test whether sacubitril-valsartan could improve outcomes for individuals with acute heart failure, the research team conducted a randomized, double-blind clinical trial called PIONEER-HF. More than 800 patients hospitalized with heart failure at 129 U.S. sites were treated with either sacubitril-valsartan or the standard therapy, enalapril, an ACE inhibitor. Over the trial period of eight weeks, the researchers monitored participants' blood pressure and other safety parameters, such as kidney function, and analyzed blood and urine samples.

The research team found that in patients taking sacubitril-valsartan, levels of a key measure of heart failure severity – NT-proBNP – reduced more quickly than with the standard therapy. Evidence of improvement was observed as early as one week into the trial, they said.

"It worked to reduce NT-proBNP rapidly and to a greater extent than enalapril," said corresponding author Eric Velazquez, M.D., the Berliner Professor of Cardiology at Yale School of Medicine and PIONEER-HF principal study investigator. "There were multiple markers including troponin T, a marker of heart cell injury, that suggested substantial improvement."

Velazquez and his co-authors also reported no significant differences between the two therapies in terms of safety, including impact on renal function, blood pressure, and other indicators. "The results of this landmark study should help inform our basic approach to treating hospitalized patients with acute heart failure," said Velazquez. "Once acute heart failure is diagnosed, patients are stabilized, and a low ejection fraction is confirmed, sacubitril/valsartan should be started promptly to reduce NT-proBNP and reduce the risk of post-discharge heart failure hospitalization."

Combined with results of a previous trial, PARADIGM-HF, which showed the drug's effectiveness for patients with chronic heart failure, these findings could make sacubitril-valsartan the go-to standard of care for acute and chronic heart failure, said the researchers.

"There are consistent results from both trials," Velazquez said. "It is safe and there's a rapid outcome. If it becomes the standard, we are likely to reduce the risk of hospitalization for heart failure, and that will have a positive clinical impact and societal impact."

Other study authors are David A. Morrow, Adam D. DeVore, Carol I. Duffy, Andrew P. Ambrosy, Kevin McCague, Ricardo Rocha, and Eugene Braunwald.

PIONEER-HF was supported by Novartis Pharmaceuticals Corporation, which conducted the trial in collaboration with the Duke Clinical Research Institute and the Thrombolysis in Myocardial Infarction Study Group.

## Cardiology特集

AHA2018 (第91回米国心臓病協会)

### トピックス一覧

[News01]

高用量EPAによる心血管疾患予防

[News02]

魚油およびビタミンDの経年による予防効果

[News03]

糖尿病治療薬は心不全を予防する

[News04]

心疾患を有する糖尿病患者においてバイパス手術は血管形成術よりも優れている

[News05]

意思決定支援ツールが心房細動の管理を改善する

[News06]

糖尿病治療薬は心臓の構造を改善する

[News07]

アンジオテンシン受容体ネプリライシン阻害薬はACE阻害薬より優れている

[News08]

メトレキサートは心血管イベントを減少させない

[News09]

エゼチミブは一次予防目的の標準治療として最良である

[News10]

PTSDは心停止後のリスクを上昇させる

[News11]

冠動脈石灰化は冠動脈リスクの優れた予測因子である

[News12]

慢性的な騒音への曝露は心血管リスクを上昇させる